Trials / Terminated
TerminatedNCT05769959
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Conditions
- Renal Cell Carcinoma
- Non-small Cell Lung Cancer
- Pancreatic Adenocarcinoma
- Colorectal Cancer
- Ovarian Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7515629 | RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort. |
| DRUG | tocilizumab | Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS). |
Timeline
- Start date
- 2023-06-15
- Primary completion
- 2024-03-19
- Completion
- 2024-03-19
- First posted
- 2023-03-15
- Last updated
- 2024-07-09
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05769959. Inclusion in this directory is not an endorsement.